X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Burden on patients: Insurance benefit design’s impact on patient access to medicines

By Allyson Funk  |    June 30, 2016
Last week, we looked at access to medicines in health insurance exchanges for HIV/AIDS, oncology, cystic fibrosis, mental health and multiple sclerosis. The analysis by Avalere Health presents...   Read More

New report celebrates a decade of progress in chronic diseases

By Holly Campbell  |    February 25, 2016
In the last 10 years, incredible progress has been made by the biopharmaceutical industry in the treatment of chronic diseases. With about half of all Americans, or 117 million people, living with...   Read More

Patient Profile: Out-of-Pocket Cost Burden for Rheumatoid Arthritis Patient

By Allyson Funk  |    April 9, 2015
Last month, we walked through how managing chronic myeloid leukemia with a health insurance exchange plan can leave patients with burdensome out-of-pocket costs and put patients’ access to...   Read More

New Evidence of Discrimination in Essential Health Benefit Plans

By Tina Stow  |    January 30, 2015
While the Affordable Care Act (ACA) expanded access to health insurance coverage for millions, a new study from the Harvard T.H. Chan School of Public Health reveals that insurers may be...   Read More

Burden on Patients: Preserving the ‘New Normal’ for Patients with Rheumatoid Arthritis

By Allyson Funk  |    June 24, 2014
In the last 20 years, medical advances have transformed the lives of Rheumatoid Arthritis (RA) patients. Instead of managing symptoms, innovative medicines help slow disease progression and can...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates